Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. A Single-Arm, Multicenter Clinical Trial
Latest Information Update: 26 Sep 2023
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Isotretinoin (Primary) ; Naxitamab (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- Sponsors SciClone Pharmaceuticals
Most Recent Events
- 26 Sep 2023 New trial record